Wardwizard Healthcare has released its FY 2025-26 annual results, showing revenue growth to Rs 0.84 crore and a narrowed net loss of Rs 0.32 crore. The company announced a 42nd AGM for September 30, 2026, where it will seek shareholder approval for a Rs 12.5 crore preferential warrant issue and a significant increase in authorized share capital to Rs 25 crore. Investors should note planned board leadership changes and material related-party transactions with Wardwizard Medicare Private Limited.
Wardwizard Healthcare Announces FY26 Results and Capital Expansion Plan
Revenue grew to Rs 0.84 crore in FY26 compared to Rs 0.42 crore in FY25.
Net loss narrowed to Rs 0.32 crore from Rs 2.71 crore in the previous fiscal year.
Reader Takeaway: Revenue has doubled and losses have narrowed significantly, though capital infusion plans indicate heavy reliance on future funding.
What just happened
Wardwizard Healthcare published its Annual Report for FY 2025-26, highlighting a performance turnaround with revenue doubling year-on-year. The company has formally scheduled its 42nd Annual General Meeting for September 30, 2026. Key board proposals include a significant hike in authorized share capital from Rs 7.50 crore to Rs 25 crore to accommodate future growth.
Why this matters
The company is signaling a major capital restructuring phase. The proposed issuance of 1.25 crore fully convertible warrants at Rs 10 per share aims to raise Rs 12.5 crore. This capital is crucial for the company’s expansion strategy, especially as it seeks to normalize operations following a period of persistent losses.
Board and Governance Update
The leadership structure is undergoing a transition. Independent Director Mitesh Ghanshyambhai Rana and Non-Executive Director Sheetal Mandar Bhalerao have resigned. The company proposes the appointment of Yuvraj Priyadarshi as Whole-time Director and Sathi Kundu as an Independent Director. Additionally, the firm is transitioning to a new statutory auditor, M/s MGSA & Company.
Risks to watch
Investors should closely track the proposed material related-party transactions with Wardwizard Medicare Private Limited, capped at Rs 50 crore annually. The approval and execution of these transactions, alongside the success of the warrant issue, are central to the company’s financial stability as it remains in a net-loss position.
What to track next
Watch for the outcome of the shareholder vote at the upcoming AGM on September 30, 2026, regarding the preferential warrant issuance and the related-party transaction mandates.